Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC

Mok, T.Nakagawa, K.Rosell, R.Lee, K.Corral, J.Migliorino, M. R.Pluzanski, A.Linke, R.Devgan, G.Sbar, E.Quinn, S.Wang, T.Wu, Y.2025-01-072025-01-072018-10-011556-0864https://hdl.handle.net/10668/27249endose reductionnon-small cell lung cancerDacomitinibEffects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLCconference outputopen access10.1016/j.jtho.2018.08.5461556-1380http://www.jto.org/article/S1556086418315041/pdf454014501181